Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   10:35:17 AM EDT
125.11
-1.40 (-1.11%)
Products, Earnings Announcements

Biohaven Announces Preliminary Q2 Net Product Revenue For NURTEC ODT

Published: 07/07/2021 11:29 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - Biohaven Announces Preliminary 2q2021 Net Product Revenue for Nurtec Odt, the First and Only Migraine Medication for Both Acute and Preventive Treatment.
Biohaven Pharmaceutical Holding Company Ltd - Nurtec Odt Achieved Preliminary Net Product Revenue of About $93 Million for Q2.
Biohaven Pharmaceutical Holding Company Ltd - Launch to Date Net Product Revenue for Nurtec Odt is Approximately $200 Million.
Revenue is expected to be $54.73 Million
Adjusted EPS is expected to be -$3.15

Next Quarter Revenue Guidance is expected to be $98.14 Million
Next Quarter EPS Guidance is expected to be -$2.60

More details on our Analysts Page.